Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma
Qin Tang , Guanghui Hu , Ye Sang , Yulu Chen , Guangyan Wei , Meiyan Zhu , Mengke Chen , Shiyong Li , Rengyun Liu , Zhenwei Peng
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (5) : e1703
Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma
• TERT promoter mutation confers sensitivity to PLK1 inhibitors in HCC. • The selective growth inhibition of TERT mutant HCC cells induced by PLK1 inhibitor was mediated by Smad3. • Combined inhibition of PLK1 and Smad3 showed a cooperative anti-tumor effect in TERT mutant HCC cells.
hepatocellular carcinoma / PLK1 / Smad3 / TERT promoter mutation
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas Research N. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327-1341 e1323. |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |